We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Ptc3.5

Phosphatidylcholine Research

Too few graded studiesHigh safety

2 peer-reviewed studies

What the evidence says

Too few graded studies

Phosphatidylcholine doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.

Most evidence is from medium-quality randomised trials published 2012–2016 with a typical study size of 179 participants.

Based on 2 studies · 2 RCTs · 179 total participants

Confidence

Low

By outcome

Liver healthImproves fatty-liver markers (mostly in phospholipid combination products) · 8-24 weeks
Too few graded studies2 studies

Older research base

Newest study from 2016

20122016

1RCTn=179 · medium study2012

A randomized trial found silybin combined with phosphatidylcholine and vitamin E improved liver markers in fatty liver disease.

Loguercio C et al. · Free Radic Biol Med (2012)

Silybin + phosphatidylcholine + vitamin E improved liver enzymes/markers in NAFLD
COMBINATION product (Realsil) — not phosphatidylcholine alone
Phospholipid improves silybin absorption

View source

2RCT2016

In a randomized acupuncture trial, polyene phosphatidylcholine was the control arm and performed worse than acupuncture on liver markers.

Huang Z et al. · Zhongguo Zhen Jiu (2016)

Polyene phosphatidylcholine was the COMPARATOR (control) arm in an acupuncture trial — it underperformed acupuncture on liver enzymes and steatosis
Does NOT support standalone phosphatidylcholine efficacy
Included for transparency, not as positive evidence

View in Research Library

Phosphatidylcholine Research

Too few graded studies

Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial.

[Non-alcoholic fatty liver disease of liver stagnation and spleen deficiency pattern treated with acupoint embedding therapy: a randomized controlled trial].